WO2002102364A1 - Preparations medicamenteuses agonistes ppar$g(g) - Google Patents
Preparations medicamenteuses agonistes ppar$g(g) Download PDFInfo
- Publication number
- WO2002102364A1 WO2002102364A1 PCT/JP2002/006066 JP0206066W WO02102364A1 WO 2002102364 A1 WO2002102364 A1 WO 2002102364A1 JP 0206066 W JP0206066 W JP 0206066W WO 02102364 A1 WO02102364 A1 WO 02102364A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- dha
- pharmaceutical composition
- acid
- agonistic
- composition according
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Definitions
- the present invention relates to a pharmaceutical composition comprising a derivative of a polyunsaturated fatty acid. More specifically, the present invention provides the above pharmaceutical composition which acts on PPAT (Peroxisome proliierator-activated receptor 7: ⁇ J rexisomal growth factor responsive receptor).
- PPAT Peroxisome proliierator-activated receptor 7: ⁇ J rexisomal growth factor responsive receptor
- the peroxisome proliferator-activated receptor was first discovered as a nuclear orphan receptor, and three genes, ⁇ , 0 (or i3), and ⁇ , have since been identified. ⁇ , hi, and a have specific tissue distributions, respectively, and constitute one of the nuclear hormone receptor gene groups. PPART is highly expressed in adipose tissue and is thought to play an important role in adipocyte differentiation and fat production.
- TZD thiazolidinedione
- ⁇ Insulin secreted from iS cells binds to insulin receptor (m) in the liver and peripheral skeletal muscle, and glucose uptake and sugar utilization via insulin receptor substrate (IRS).
- m insulin receptor
- IRS insulin receptor substrate
- Kadowaki et al.'S group created insulin-resistant but non-diabetic mice by creating a mouse -1 gene, the ms-1 gene, one of the IRS subtypes ('00 J.
- PPARrKO mice Kadowaki and colleagues attempted to generate PPARrKO mice to investigate the direct effects of. Since homozygous KO mice (null) of both genes showed embryonic lethality for pulmonary insufficiency, they were analyzed for convenience using heterozygous KO mice. It showed weight loss and suppressed adipocyte differentiation, suggesting that FPARr may act as an energy storage gene for starvation ('99 Moll. Cell 4 p. 597). In other words, it states that PPARr accumulates energy by increasing the number of fat cells and maintains carbohydrate and lipid homeostasis.
- TZD lowers blood glucose by both the action of PPARa to normalize the insulin signal and the action of adipocyte differentiation, but TZD has the problem of causing strong side effects.
- Some TZDs marketed as insulin sensitizers have been shown to have severe liver damage and have been discontinued, and some have been reported to have died from liver damage. Therefore, there is a need for a drug for treating diabetes through PPARr, which does not exhibit side effects like TZD.
- PPARr agonists not only improve NIDDM, but also have the effects of improving high TG (triacylglycerol) blood pressure, lowering cholesterol, etc., and improving lipid levels. ('98 Diabetologia 41, .257).
- hydroxylated metabolites of arachidonic acid such as leukotriene-prostaglandin cause pain, tissue damage and fever via neutrophil activation, platelet aggregation, vasoconstriction and the like.
- DHA docosahexaenoic acid
- PUFA highly unsaturated fatty acid
- EPA eicosapentaenoic acid
- lipoxygenase activity has also been reported on platelets and intestinal epithelial cells.For example, it has been shown that 11 OH-DHA and 14 OH-DHA are metabolized from exogenous DHA in human platelets . In addition, it was confirmed that stimulation of rat platelets fed with fish oil with Ca 2+ ionophore released 1.4 micro 14OH-DHA. However, when compared with the above-mentioned IC 25 value, which is the 25 % inhibition point of vascular smooth muscle contraction by 14 OH-DHA, it can be seen that both are almost equivalent.
- the concentration of 14 OH-DHA in the mammal matches the concentration range in which the anti-inflammatory effect can be exhibited, and 14 OH-DHA is actively involved in maintaining homeostasis in the animal. It is suggested that there is a possibility.
- An object of the present invention is to develop a novel PPARr agonist pharmaceutical composition and provide it as a therapeutic agent for various diseases involving PPARr.
- the present invention provides a PPART agonistic pharmaceutical composition comprising a hydroxylated derivative of a polyunsaturated fatty acid having a carbon chain length of 20 to 22 or a pharmaceutically acceptable salt thereof.
- a PPARr-agonist pharmaceutical composition is used to prevent and treat various diseases involving PPART by acting on and activating PPART which is a nuclear receptor of cells such as adipocytes. Refers to pharmaceutical products.
- the present invention further provides the above PPARr agonist pharmaceutical composition for treating a cardiovascular disease.
- the present invention further provides the above PPART agonistic pharmaceutical composition for treating arteriosclerosis.
- the present invention further provides the above PPAR agonistic pharmaceutical composition for treating a lipid metabolism disease.
- the present invention further provides a PPARr agonist pharmaceutical composition for treating diabetes.
- the present invention further provides a PPARergic pharmaceutical composition for treating an inflammatory disease.
- FIG. 1 is a graph showing the results of a PPAR agonist test of various OH-DHA compounds.
- FIG. 2 is a graph showing the results of examining whether 4 (S) -OH-DHA inhibits ex vivo platelet aggregation induced by collagen.
- FIG. 3 is a graph showing the results of examining whether (S) -0H-DHA suppresses ex vivo platelet aggregation in a dose-dependent manner.
- FIG. 4 is a graph showing the effect of 4 (S) -OH-DHA on the interaction between neutrophils and vascular endothelial cells (neutrophil migration rate (%)).
- FIG. 5 is a graph showing the effect of 4 (S) -0H-DHA on the interaction between neutrophils and vascular endothelial cells (neutrophil adhesion (%)).
- the PPARr agonist pharmaceutical composition of the present invention contains a hydroxylated derivative of a polyunsaturated fatty acid having a carbon chain length of 20 to 22 as an active ingredient.
- the polyunsaturated fatty acid having a carbon chain length of 20 to 22 refers to an unsaturated fatty acid having a carbon chain length of 20 to 22 and containing three or more double bonds.
- the number of double bonds is preferably 4 or more, more preferably 5 or 6.
- Preferred highly unsaturated fatty acids are docosahexaenoic acid (DHA, 22: 6n-3) (a linear unsaturated fatty acid having a carbon chain length of 22, n-3 and an unsaturated number of 6) and eicosapentaenoic acid (EPA, 20: 5n-3) (A straight-chain unsaturated fatty acid with a carbon chain length of 20 and n-3 series and an unsaturated number of 5), but is not limited to this.
- DHA docosahexaenoic acid
- EPA eicosapentaenoic acid
- the hydroxylated derivative of a polyunsaturated fatty acid refers to a derivative of a polyunsaturated fatty acid in which one of the double bonds is hydroxylated, and is a hydroxylated derivative of docosahexaenoic acid (DHA) or water of eicosapentaenoic acid (EPA). Oxidized derivatives are preferred, and hydroxylated derivatives of docosahexaenoic acid (DHA) are more preferred.
- the configuration of the hydroxylated derivative may be either the (R) configuration or the (S) configuration, but is preferably the (S) configuration.
- the most preferred hydroxylated derivatives of docosahexaenoic acid are 4 (S) -OH-DHA, 10 (S) -OH-DHA, 11 (S) -OH-DHA 14 (S) -OH- DHA, 8 (S)-OH-DHA> And 17 (S) -OH-DHA, but is not limited thereto.
- the PPARr agonist pharmaceutical composition of the present invention can contain one or more hydroxylated derivatives of polyunsaturated fatty acids selected from these.
- the hydroxylated derivative of a polyunsaturated fatty acid may be produced by any method, for example, it is separated and purified from fish gills, epithelial cells, etc., or from human blood platelets such as humans and rats. May be.
- the DHA may be synthesized by hydroxylating naturally occurring DHA and fractionating it by HPLC or the like, and there is no particular limitation. For example, add 10-200 mM DHA as a substrate to rainbow trout gill cells, epithelial cells, mammalian platelets, or a suspension of human leukocyte-derived cell lines such as RBL-1 at 10-37 ° C for 1-50 minutes. It can also be obtained by reacting.
- the reaction was stopped by making the reaction solution acidic (formic acid, acetic acid, trichloroacetic acid, etc.), and each OH derivative was extracted with an organic solvent (chloroform, methanol, ethyl acetate, acetonitrile, etc.). After that, it can be fractionated by HPLC or thin-layer chromatography using a developing solvent (eg, chloroform, methanol, ethyl acetate, acetonitrile, water, or trifluoroacetic acid). It is not something to be done.
- Each OH derivative can also be prepared by a selective synthesis method using a site-specific enzyme.
- PPART is a nuclear receptor of cells such as adipocytes, to prevent and treat various diseases involving PPAR. It is valid.
- PPART-related diseases include circulatory diseases (eg, thrombosis, myocardial infarction, angina, cerebral infarction, etc.), arteriosclerosis, lipid metabolism (eg, hyperlipidemia, hypercholesterolemia, These include, but are not limited to, high TG disease, high LDL disease, diabetes mellitus (particularly NIDDM), and inflammatory diseases (eg, various inflammatory reactions caused by vascular permeability enhancement).
- the PPART agonistic pharmaceutical composition of the present invention is usually administered systemically or locally, orally or parenterally.
- the dosage depends on the type of disease, degree of symptoms, Judgment should be made comprehensively based on various conditions such as age and weight, and the optimal amount should be determined as appropriate, and there is no particular limitation. However, for adults, it is usually 0.001 to: L00 mg / kg per day for oral administration and 0.0001 to 10 mg / kg for parenteral administration per day. Administration may be performed once or multiple times daily as needed.
- the hydroxylated derivative of a polyunsaturated fatty acid which is the active ingredient of the present invention may be a pharmaceutically acceptable salt thereof.
- Pharmaceutically acceptable salts include acid addition salts, for example, methanesulfonate, fumarate, hydrochloride, citrate, maleate, tartaric acid, and hydrobromide.
- compositions of the present invention may be administered in any form of solid composition, liquid composition and other compositions by oral administration, parenteral administration such as injection, external preparation, suppository and the like.
- oral administration parenteral administration
- parenteral administration such as injection, external preparation, suppository and the like.
- the most suitable method is selected according to.
- Pharmaceutical compositions can be prepared using carriers, excipients, and other additives that are commonly used in pharmaceutical formulations.
- Pharmaceutical carriers and excipients include, for example, lactose, magnesium stearate, starch, talc, gelatin, agar, pectin, gum arabic, olive oil, sesame oil, potato whey, ethylene glycol, and others. You can give things.
- At least one active substance comprises at least one inert diluent, such as lactose, mannitol, glucose, hydroxypropylcellulose, microcrystalline cellulose, starch. , Polyvier pyrrolidone, magnesium metasilicate, etc.
- the composition may contain additives other than diluents which are inactive according to conventional methods, e.g., lubricating agents such as magnesium stearate, disintegrating agents such as calcium cellulose glycolate, glutamic acid or aspartic acid. A solubilizing agent may be included.
- the tablets or pills may be coated with a sugar coating such as sucrose, gelatin, hydroxypropyl methylcellulose phthalate, a film of a gastric or enteric substance, or two or more layers, if necessary. Also included are capsules of absorbable materials such as gelatin.
- Liquid compositions for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, It contains syrups, elixirs and the like, and may contain commonly used inert diluents, for example, purified water, ethanol and the like.
- the composition may contain, in addition to the inert diluent, adjuvants such as wetting agents and suspending agents, sweetening agents, flavoring agents, flavoring agents, preservatives, and the like.
- Injections for parenteral administration include sterile aqueous or non-aqueous solutions, suspensions, and emulsions.
- Aqueous solutions and suspensions include, for example, water for injection and physiological saline for injection.
- Non-aqueous solutions and suspensions include, for example, propylene glycol, polyethylene glycol, vegetable oils such as olive oil, alcohols such as ethanol, Polysorbate 80 (registered trademark), and the like. It is.
- Such compositions may also contain adjuvants such as preservatives, wetting agents, emulsifying agents, dispersing agents, stabilizing agents (eg, lactose), and solubilizing agents (eg, glutamic acid, aspartic acid). Is also good.
- a sterile solid composition can be produced and dissolved in sterile water or a sterile solvent for injection before use.
- compositions for parenteral administration include at least one of the compounds of the present invention as an active ingredient, and are externally formulated, ointments, liniments, suppositories, transdermals, and eye drops prescribed by ordinary methods. And so on.
- the active ingredient may be prepared as an OZW type emulsion preparation (emulsion) using a phospholipid or a nonionic surfactant as an emulsifier, as described in JP-A-6-298642. it can.
- the emulsifiers can be used alone or in combination of two or more. The amount of the emulsifiers may be appropriately determined, but is preferably 0.01 to 10% (W / V), preferably 0.01 to 5%. (W / V).
- soybean-derived phospholipids soybean-derived phospholipids, egg yolk-derived phospholipids, lysolecithin, phosphatidylcholine (lecithin), phosphatidylserine, and the like can be used alone or in combination.
- non-surfactant examples include a polyoxyethylene-polyoxypropylene block copolymer having a molecular weight of 500 to 1500 (for example, Pull Mic F-68), a molecular weight of 100 to 100 Polyalkylene glycol having a molecular weight of 100, a polyoxyalkylene copolymer having a molecular weight of 100 to 200, and a cured cast resin
- Polyoxyalkylene derivative of castor oil, polyoxyalkylene derivative of castor oil, fatty acid ester of dali serine, fatty acid ester of polyglycerin, sorbitan fatty acid ester, polyoxyethylene castor oil, hydrogenated castor oil, polyoxyethylene alkyl ether, sucrose fatty acid Ester or the like may be used alone or in combination, but is not limited thereto.
- DHA docosahexaenoic acid
- DHA docosahexaenoic acid
- the hydroxylated derivative of a polyunsaturated fatty acid which is an active ingredient of the pharmaceutical composition of the present invention, is a substance derived from a natural product, and can be expected to have few side effects such as toxicity. Therefore, the PPART agonist pharmaceutical composition of the present invention is particularly useful as a therapeutic agent for diabetes that does not exhibit side effects such as TZD, particularly as a preventive and / or therapeutic agent for type 2 diabetes (NIDDM). Further, the PPART agonistic pharmaceutical composition of the present invention can be expected to be effective as a therapeutic drug for inflammatory diseases.
- the reaction solution was extracted with ethyl acetate, and lipids were fractionated by HPLC using chloroform: methanol: acetic acid: water (90: 8: 1: 0.8) as a developing solvent.
- the product was analyzed by GC-MS, and 4 (S) -OH-DHA, 10 (S) -OH-DHA, 11 (S) -OH-DHA, 14 (S) -OH-DHA (m / z 430 [ M], 373 [M - CH 3] +, 340 [M- HOSi (CH 3) 3] +), 8 (S) - OH - to give the OH -DHA - DHA, and 17 (S).
- These compounds can also be purchased from Wako Pure Chemical.
- Example 2 PPART operability test
- DHA (Cayman Chemical) and EPA (Cayman Chemical) were tested using 3 microM each as a test substance.
- DHA significantly increased the PPARa transcription activity at a negative control ratio of 205 ⁇ 79% at 3 microM.
- EPA did not show any effect at a concentration of 3 microM.
- Example 1 8 (S) -OH-DHA, 10 (S) -OH -DHA. 11 (S)-OH-DHA, 14 (S)-OH-DHA and 17 (S)-OH-DHA as test substances, known to be PPARr ligands 15 deoxy-PG J2 (BioMol) was tested for PPARr operability with positive symmetry.
- PPARr agonist acts on vascular endothelial cells by suppressing the expression of ICAM-1, an adhesion molecule induced by TNF, thereby reducing the adhesion of inflammatory cells to vascular endothelial cells and suppressing inflammation.
- ICAM-1 an adhesion molecule induced by TNF
- PPARr agonist acts on vascular endothelial cells by suppressing the expression of ICAM-1, an adhesion molecule induced by TNF, thereby reducing the adhesion of inflammatory cells to vascular endothelial cells and suppressing inflammation.
- Pseudovascular in vitro inflammation model was created according to the method described in Biopharmaceutical Science Laboratory Course, 12 Inflammation and Allergy II, p.327-341 (edited by Kazuo Ouchi, Hirokawa Shoten, published May 15, 1993). did.
- neutrophils penetrate from the upper chamber through the vascular endothelial cell layer and penetrate to the lower chamber, and adhere to the endothelial cell layer, in response to TNFa inside the blood vessel. It mimics the movement of neutrophils from blood vessels to sites of inflammation.
- the neutrophil migration rate and adhesion rate were expressed as relative values of the neutrophil migration number and adhesion number in the drug administration group relative to the neutrophils in the negative control group.
- FIGS. 4 (S) -0H-DHA inhibited both neutrophil adhesion and permeation. That is, 4 (S) -OH-DHA inhibits the interaction between neutrophils and endothelial cells. It was suggested that it might work in a systemic manner and work in the direction of anti-inflammatory.
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP02733509A EP1407767A4 (en) | 2001-06-18 | 2002-06-18 | AGONIST MEDICINAL PREPARATIONS PPAR $ G (G) |
US10/481,120 US20040176451A1 (en) | 2001-06-18 | 2002-06-18 | Pparg agonistic medicinal compositions |
JP2003504951A JPWO2002102364A1 (ja) | 2001-06-18 | 2002-06-18 | PPARγ作動性医薬組成物 |
US11/277,123 US20060142391A1 (en) | 2001-06-18 | 2006-03-21 | Ppargamma-activating pharmaceutical composition |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2001-182731 | 2001-06-18 | ||
JP2001182731 | 2001-06-18 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/277,123 Division US20060142391A1 (en) | 2001-06-18 | 2006-03-21 | Ppargamma-activating pharmaceutical composition |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2002102364A1 true WO2002102364A1 (fr) | 2002-12-27 |
Family
ID=19022766
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2002/006066 WO2002102364A1 (fr) | 2001-06-18 | 2002-06-18 | Preparations medicamenteuses agonistes ppar$g(g) |
Country Status (4)
Country | Link |
---|---|
US (2) | US20040176451A1 (ja) |
EP (1) | EP1407767A4 (ja) |
JP (1) | JPWO2002102364A1 (ja) |
WO (1) | WO2002102364A1 (ja) |
Cited By (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005272410A (ja) * | 2004-03-26 | 2005-10-06 | Ajinomoto Co Inc | 抗動脈硬化用及び/又は血液レオロジー改善用経口アミノ酸組成物 |
JP2006030037A (ja) * | 2004-07-16 | 2006-02-02 | Biomolecular Engineering Research Institute | 受容体リガンド同定法 |
WO2007049586A1 (ja) * | 2005-10-24 | 2007-05-03 | Keiko Yamamoto | 潰瘍性大腸炎及び/又はクローン病治療剤 |
JPWO2005083070A1 (ja) * | 2004-03-01 | 2008-01-17 | ファルマフロンティア株式会社 | 血糖値の低下に供される医薬組成物 |
WO2008047633A1 (fr) * | 2006-10-10 | 2008-04-24 | Maruha Corporation | Agent de blanchiment de la peau contenant un composé aliphatique |
EP1675588A4 (en) * | 2003-10-22 | 2010-04-21 | Univ Rochester | USE OF PEROXISOME PROLIFERATORS (PPAR GAMMA) AND / OR RETINOIC ACID RECEPTOR ACTIVATED GAMMA AGONISTS (RXR) TO INHIBIT PLATELET FUNCTIONS |
JP2013500966A (ja) * | 2009-07-31 | 2013-01-10 | ユニバーシティー オブ ピッツバーグ − オブ ザ コモンウェルス システム オブ ハイヤー エデュケーション | 抗炎症剤としての脂肪酸 |
JP2013063913A (ja) * | 2011-09-15 | 2013-04-11 | Idemitsu Kosan Co Ltd | Gpr119アゴニスト並びにそれを含むインスリン分泌促進剤、血糖降下剤および糖尿病の治療または予防剤 |
JP2015091246A (ja) * | 2008-07-18 | 2015-05-14 | ヒルズ・ペット・ニュートリシャン・インコーポレーテッド | 高齢の動物の生活の質を向上させるための方法 |
JP2015140323A (ja) * | 2014-01-29 | 2015-08-03 | 岩手県 | Ppar活性化剤 |
JP2015522535A (ja) * | 2012-05-10 | 2015-08-06 | ソルテックス エヌエー エルエルシー | 天然の特異的炎症収束性メディエータおよびその前駆物質を含有する、抗炎症活性を有する油 |
US9585855B2 (en) | 2008-06-19 | 2017-03-07 | The University Of Utah Research Foundation | Use of nitrated lipids for treatment of side effects of toxic medical therapies |
US9663444B2 (en) | 2009-10-02 | 2017-05-30 | Complexa, Inc. | Heteroatom containing substituted fatty acids |
US9700534B2 (en) | 2007-08-01 | 2017-07-11 | University of Pittsburgh—of the Commonwealth System of Higher Education | Nitrated-fatty acids modulation of type II diabetes |
US9790167B2 (en) | 2008-05-01 | 2017-10-17 | Complexa, Inc. | Vinyl substituted fatty acids |
US10010532B2 (en) | 2011-08-19 | 2018-07-03 | The University Of Utah Research Foundation | Combination therapy with nitrated lipids and inhibitors of the renin-angiotensin-aldosterone system |
US10369125B2 (en) | 2008-06-19 | 2019-08-06 | The University Of Utah Research Foundation | Method of treating renal system damage |
JP2019210239A (ja) * | 2018-06-02 | 2019-12-12 | 学校法人 岩手医科大学 | 8−ヒドロキシエイコサペンタエン酸の薬理用途 |
US10537541B2 (en) | 2015-10-02 | 2020-01-21 | Complexa Inc. | Treatment of focal segmental glomerular sclerosis (FSGS) using therapeutically effective oral doses of 10-nitro-9(E)-octadec-9-enoic acid |
US10653703B2 (en) | 2015-09-03 | 2020-05-19 | Solutex Na Llc | Compositions comprising omega-3 fatty acids, 17-HDHA and 18-HEPE and methods of using same |
US11608342B2 (en) | 2015-07-07 | 2023-03-21 | H. Lundbeck A/S | PDE9 inhibitors with imidazo triazinone backbone and imidazo pyrazinone backbone for treatment of peripheral diseases |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009149496A1 (en) * | 2008-06-10 | 2009-12-17 | Central Northern Adelaide Health Service | Treatment of diabetes and complications thereof and related disorders |
KR101372037B1 (ko) * | 2010-04-06 | 2014-03-10 | (주)아모레퍼시픽 | 근육 타입 변화를 촉진하는 조성물 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6317825A (ja) * | 1986-07-11 | 1988-01-25 | Teijin Ltd | 創傷治癒促進剤 |
JPH05186342A (ja) * | 1992-01-10 | 1993-07-27 | Fujirebio Inc | 免疫調節作用を併せもつ抗炎症剤 |
WO1996034943A1 (en) * | 1995-05-04 | 1996-11-07 | City Of Hope | Human leukocyte 12-lipoxygenase and its role in the pathogenesis of disease states |
JP2000355538A (ja) * | 1999-04-15 | 2000-12-26 | Kanegafuchi Chem Ind Co Ltd | ペルオキシゾーム活性化剤応答性受容体アゴニスト |
JP2001354558A (ja) * | 2000-06-12 | 2001-12-25 | Kao Corp | Ppar活性化剤 |
JP2002186424A (ja) * | 2000-10-12 | 2002-07-02 | Kanegafuchi Chem Ind Co Ltd | 共役トリエン酸系油脂を含有する飲食品 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2107062A (en) * | 1936-03-17 | 1938-02-01 | Armour & Co | Hydroxylated fish oil fatty acids and processes of preparing the same |
GB2223943A (en) * | 1988-10-21 | 1990-04-25 | Tillotts Pharma Ag | Oral disage forms of omega-3 polyunsaturated acids |
JPH0672868A (ja) * | 1992-08-26 | 1994-03-15 | Maruha Corp | 抗精神病薬 |
US6191154B1 (en) * | 1998-11-27 | 2001-02-20 | Case Western Reserve University | Compositions and methods for the treatment of Alzheimer's disease, central nervous system injury, and inflammatory diseases |
AU775774C (en) * | 1999-04-15 | 2005-05-19 | Kaneka Corporation | Peroxisome proliferator-activated receptor agonist |
GB9916536D0 (en) * | 1999-07-14 | 1999-09-15 | Scarista Limited | Nutritional or pharmaceutical compositions |
WO2001060778A2 (en) * | 2000-02-16 | 2001-08-23 | The Brigham And Women's Hospital, Inc. | Aspirin-triggered lipid mediators |
EP1408030B1 (en) * | 2001-06-18 | 2006-01-04 | Maruha Corporation | Novel aliphatic compound, method of synthesis, and method of utilization |
-
2002
- 2002-06-18 US US10/481,120 patent/US20040176451A1/en not_active Abandoned
- 2002-06-18 WO PCT/JP2002/006066 patent/WO2002102364A1/ja active Application Filing
- 2002-06-18 JP JP2003504951A patent/JPWO2002102364A1/ja active Pending
- 2002-06-18 EP EP02733509A patent/EP1407767A4/en not_active Withdrawn
-
2006
- 2006-03-21 US US11/277,123 patent/US20060142391A1/en not_active Abandoned
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6317825A (ja) * | 1986-07-11 | 1988-01-25 | Teijin Ltd | 創傷治癒促進剤 |
JPH05186342A (ja) * | 1992-01-10 | 1993-07-27 | Fujirebio Inc | 免疫調節作用を併せもつ抗炎症剤 |
WO1996034943A1 (en) * | 1995-05-04 | 1996-11-07 | City Of Hope | Human leukocyte 12-lipoxygenase and its role in the pathogenesis of disease states |
JP2000355538A (ja) * | 1999-04-15 | 2000-12-26 | Kanegafuchi Chem Ind Co Ltd | ペルオキシゾーム活性化剤応答性受容体アゴニスト |
JP2001354558A (ja) * | 2000-06-12 | 2001-12-25 | Kao Corp | Ppar活性化剤 |
JP2002186424A (ja) * | 2000-10-12 | 2002-07-02 | Kanegafuchi Chem Ind Co Ltd | 共役トリエン酸系油脂を含有する飲食品 |
Non-Patent Citations (1)
Title |
---|
See also references of EP1407767A4 * |
Cited By (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1675588A4 (en) * | 2003-10-22 | 2010-04-21 | Univ Rochester | USE OF PEROXISOME PROLIFERATORS (PPAR GAMMA) AND / OR RETINOIC ACID RECEPTOR ACTIVATED GAMMA AGONISTS (RXR) TO INHIBIT PLATELET FUNCTIONS |
JPWO2005083070A1 (ja) * | 2004-03-01 | 2008-01-17 | ファルマフロンティア株式会社 | 血糖値の低下に供される医薬組成物 |
JP4757190B2 (ja) * | 2004-03-01 | 2011-08-24 | ファルマフロンティア株式会社 | 血糖値の低下に供される医薬組成物 |
JP2005272410A (ja) * | 2004-03-26 | 2005-10-06 | Ajinomoto Co Inc | 抗動脈硬化用及び/又は血液レオロジー改善用経口アミノ酸組成物 |
JP2006030037A (ja) * | 2004-07-16 | 2006-02-02 | Biomolecular Engineering Research Institute | 受容体リガンド同定法 |
JP4525221B2 (ja) * | 2004-07-16 | 2010-08-18 | アステラス製薬株式会社 | 受容体リガンド同定法 |
WO2007049586A1 (ja) * | 2005-10-24 | 2007-05-03 | Keiko Yamamoto | 潰瘍性大腸炎及び/又はクローン病治療剤 |
WO2008047633A1 (fr) * | 2006-10-10 | 2008-04-24 | Maruha Corporation | Agent de blanchiment de la peau contenant un composé aliphatique |
JP4954988B2 (ja) * | 2006-10-10 | 2012-06-20 | 株式会社マルハニチロ水産 | 脂肪族化合物含有美白剤 |
US10869850B2 (en) | 2007-08-01 | 2020-12-22 | University of Pittsburgh—of the Commonwealth System of Higher Education | Nitrated-fatty acids modulation of type II diabetes |
US10258589B2 (en) | 2007-08-01 | 2019-04-16 | University of Pittsburgh—of the Commonwealth System of Higher Education | Nitrated-fatty acids modulation of type II diabetes |
US10576051B2 (en) | 2007-08-01 | 2020-03-03 | University of Pittsburgh—of the Commonwealth System of Higher Education | Nitrated-fatty acids modulation of type II diabetes |
US9700534B2 (en) | 2007-08-01 | 2017-07-11 | University of Pittsburgh—of the Commonwealth System of Higher Education | Nitrated-fatty acids modulation of type II diabetes |
US9790167B2 (en) | 2008-05-01 | 2017-10-17 | Complexa, Inc. | Vinyl substituted fatty acids |
US9585855B2 (en) | 2008-06-19 | 2017-03-07 | The University Of Utah Research Foundation | Use of nitrated lipids for treatment of side effects of toxic medical therapies |
US10568857B2 (en) | 2008-06-19 | 2020-02-25 | The University Of Utah Research Foundation | Method of treating renal system damage |
US10369125B2 (en) | 2008-06-19 | 2019-08-06 | The University Of Utah Research Foundation | Method of treating renal system damage |
JP2015091246A (ja) * | 2008-07-18 | 2015-05-14 | ヒルズ・ペット・ニュートリシャン・インコーポレーテッド | 高齢の動物の生活の質を向上させるための方法 |
US9066902B2 (en) | 2009-07-31 | 2015-06-30 | University of Pittsburgh—of the Commonwealth System of Higher Education | Fatty acids as anti-inflammatory agents |
JP2013500966A (ja) * | 2009-07-31 | 2013-01-10 | ユニバーシティー オブ ピッツバーグ − オブ ザ コモンウェルス システム オブ ハイヤー エデュケーション | 抗炎症剤としての脂肪酸 |
US9750725B2 (en) | 2009-07-31 | 2017-09-05 | University of Pittsburgh—of the Commonwealth System of Higher Education | Fatty acids as anti-inflammatory agents |
US9663444B2 (en) | 2009-10-02 | 2017-05-30 | Complexa, Inc. | Heteroatom containing substituted fatty acids |
US10709690B2 (en) | 2011-08-19 | 2020-07-14 | The University Of Utah Research Foundation | Combination therapy with nitrated lipids and inhibitors of the renin-angiotensin-aldosterone system |
US10010532B2 (en) | 2011-08-19 | 2018-07-03 | The University Of Utah Research Foundation | Combination therapy with nitrated lipids and inhibitors of the renin-angiotensin-aldosterone system |
JP2013063913A (ja) * | 2011-09-15 | 2013-04-11 | Idemitsu Kosan Co Ltd | Gpr119アゴニスト並びにそれを含むインスリン分泌促進剤、血糖降下剤および糖尿病の治療または予防剤 |
US10568858B2 (en) | 2012-05-10 | 2020-02-25 | Solutex Na Llc | Oils with anti-inflammatory activity containing natural specialized proresolving mediators and their precursors |
US11077083B2 (en) | 2012-05-10 | 2021-08-03 | Solutex Na Llc | Oils with anti-inflammatory activity containing natural Specialized Proresolving Mediators and their precursors |
JP2018193378A (ja) * | 2012-05-10 | 2018-12-06 | ソルテックス エヌエー エルエルシー | 天然の特異的炎症収束性メディエータおよびその前駆物質を含有する、抗炎症活性を有する油 |
JP2015522535A (ja) * | 2012-05-10 | 2015-08-06 | ソルテックス エヌエー エルエルシー | 天然の特異的炎症収束性メディエータおよびその前駆物質を含有する、抗炎症活性を有する油 |
US11865096B2 (en) | 2012-05-10 | 2024-01-09 | Solutex Na Llc | Oils with anti-inflammatory activity containing natural specialized proresolving mediators and their precursors |
US11285126B2 (en) | 2012-05-10 | 2022-03-29 | Solutex Na Llc | Oils with anti-inflammatory activity containing natural specialized proresolving mediators and their precursors |
US11077084B2 (en) | 2012-05-10 | 2021-08-03 | Solutex Na Llc | Oils with anti-inflammatory activity containing natural specialized proresolving mediators and their precursors |
JP2015140323A (ja) * | 2014-01-29 | 2015-08-03 | 岩手県 | Ppar活性化剤 |
US11608342B2 (en) | 2015-07-07 | 2023-03-21 | H. Lundbeck A/S | PDE9 inhibitors with imidazo triazinone backbone and imidazo pyrazinone backbone for treatment of peripheral diseases |
US10653703B2 (en) | 2015-09-03 | 2020-05-19 | Solutex Na Llc | Compositions comprising omega-3 fatty acids, 17-HDHA and 18-HEPE and methods of using same |
US11020406B2 (en) | 2015-09-03 | 2021-06-01 | Solutex Na Llc | Compositions comprising omega-3 fatty acids, 17-HDHA and 18-HEPE and methods of using same |
US11559529B2 (en) | 2015-09-03 | 2023-01-24 | Solutex Na Llc | Compositions comprising Omega-3 fatty acids, 17-HDHA and 18-HEPE and methods of using same |
US11833158B2 (en) | 2015-09-03 | 2023-12-05 | Solutex Na Llc | Compositions comprising omega-3 fatty acids, 17-HDHA and 18-HEPE and methods of using same |
US10537541B2 (en) | 2015-10-02 | 2020-01-21 | Complexa Inc. | Treatment of focal segmental glomerular sclerosis (FSGS) using therapeutically effective oral doses of 10-nitro-9(E)-octadec-9-enoic acid |
JP2019210239A (ja) * | 2018-06-02 | 2019-12-12 | 学校法人 岩手医科大学 | 8−ヒドロキシエイコサペンタエン酸の薬理用途 |
Also Published As
Publication number | Publication date |
---|---|
US20060142391A1 (en) | 2006-06-29 |
EP1407767A4 (en) | 2007-01-24 |
EP1407767A1 (en) | 2004-04-14 |
JPWO2002102364A1 (ja) | 2004-09-30 |
US20040176451A1 (en) | 2004-09-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2002102364A1 (fr) | Preparations medicamenteuses agonistes ppar$g(g) | |
Kimura et al. | Free fatty acid receptors in health and disease | |
Christofides et al. | The role of peroxisome proliferator-activated receptors (PPAR) in immune responses | |
US8008282B2 (en) | Lipoxin analogs as novel inhibitors of angiogenesis | |
JP4954714B2 (ja) | 脂肪毒性の改善剤 | |
EP1285652B1 (en) | Novel fatty acid analogues for the treatment of hypertension | |
JP5827784B2 (ja) | ビタミンk2を含む医薬及び栄養補助製品 | |
CN109640993B (zh) | 包含阿莫地喹及抗糖尿病药物作为有效成分的用于预防或治疗糖尿病的药学组合物 | |
JP4869942B2 (ja) | インスリン感受性/抵抗性、糖尿病および肥満におけるrbp4 | |
CA2502297C (en) | Compounds for the treatment of metabolic disorders | |
US8017652B2 (en) | Activators of peroxisome proliferator-activated receptors | |
US20120128770A1 (en) | Treatment of insulin resistance and obesity by stimulating glp-1 release | |
WO2000035867A1 (fr) | Nouveaux ligands d'un recepteur nucleaire | |
JP2016512544A (ja) | ドコサペンタエン酸を含む組成物、および使用方法 | |
KR101413616B1 (ko) | 트리글리세라이드, 콜레스테롤 및 글루코스 농도를 낮추기 위한 인다졸메톡시알카노산의 용도 | |
TWI344366B (en) | Pharmaceutical compositions for the treatment of renal dysfunction, disease or disorder, in particular in diabetic patients | |
JP2005232005A (ja) | 新規脂肪族化合物、合成方法、利用方法 | |
JP4303103B2 (ja) | 新規脂肪族化合物、合成方法、利用方法 | |
JP5504405B2 (ja) | 血管病予防に効果を有する食品組成物 | |
JP5044775B2 (ja) | 糖尿病性腎症の治療用医薬組成物 | |
AU2005306488A1 (en) | Use of methyl pyruvate to increase cellular energy production downstream of glycolysis | |
JP3917825B2 (ja) | 血管新生抑制剤 | |
EP1949937B1 (en) | Lipoxin analogs as novel inhibitors of restenosis | |
CN113905740A (zh) | 用于治疗微血管功能障碍的5,6-dihete内酯 | |
van Tol et al. | ELEVATED PLASMA PHOSPHOLIPID TRANSFER PROTEIN ACTIVITY IS A DETERMINANT OF CAROTID INTIMA-MEDIA THICKNESS IN TYPE 2 DIABETES MELLITUS |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 10481120 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003504951 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002733509 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2002733509 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |